Medincell Publishes Its Consolidated Annual Financial Results [Yahoo! Finance]
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
Highlights Commercial launch by Teva Pharmaceuticals ("Teva") of UZEDY ® (risperidone) in the U.S., the first product using Medincell BEPO ® technology Successful commercial launch and market access negotiations with U.S. private and public health insurance systems Receipt of a €3.6 million milestone payment for U.S. FDA approval and €1.7 million in royalties received on first net sales Sales ramp-up in line with forecasts: $80 million in revenue anticipated by Teva in 2024 Acceleration of phase 3 clinical trial of mdc-TJK (olanzapine, schizophrenia), second antipsychotic developed with Teva End of recruitment in January 2024, 9 months earlier than originally planned Post-closing Announcement of positive phase 3 efficacy results in May 2024 No post-injection delirium/sedation syndrome (PDSS) observed after administration of approximately 80% of the number of injections required by the FDA, as of May 8, 2024 End of phase 3 clinical trial of mdc-CWM (intraarticular
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Global Anal Fissure Treatment Market Size To Exceed USD 1986.1 Million By 2033 | CAGR Of 5.51% [Yahoo! Finance]Yahoo! Finance
- ADHD Drug Shortage Could Worsen After Arrests Of 2 Telehealth Executives, CDC Warns [Forbes]Forbes
- ACTO ACQUIRES 4TH DOWN SOLUTIONS, BRINGING TOGETHER TWO INDUSTRY LEADERS [Yahoo! Finance]Yahoo! Finance
- Medincell Joins the Euronext Tech Leaders [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $20.00 to $21.00. They now have an "overweight" rating on the stock.MarketBeat
TEVA
Earnings
- 5/8/24 - Miss
TEVA
Sec Filings
- 6/21/24 - Form 4
- 6/18/24 - Form 144
- 6/17/24 - Form 4
- TEVA's page on the SEC website